Pharmacology of 5-Aza-2'-deoxycytidine (decitabine)MOMPARLER, Richard L.Seminars in hematology. 2005, Vol 42, Num 3, pp S9-S16, issn 0037-1963, SUP2Article

Decitabine dosing schedulesKANTARJIAN, Hagop M; ISSA, Jean-Pierre J.Seminars in hematology. 2005, Vol 42, Num 3, pp S17-S22, issn 0037-1963, SUP2Article

Issues regarding study design for initial clinical trials using decitabineDEBAUN, Michael R.Seminars in hematology. 2004, Vol 41, Num 4, pp 23-27, issn 0037-1963, 5 p., SUP6Conference Paper

Epigenetic therapy of cancer with 5-aza-2'-deoxycytidine (decitabine)MOMPARLER, Richard L.Seminars in oncology. 2005, Vol 32, Num 5, pp 443-451, issn 0093-7754, 9 p.Article

Dual antitumour effect of 5-azacytidine by inducing a breakdown of resistance-mediating factors and epigenetic modulationVENTURELLI, Sascha; BERGER, Alexander; FULDA, Simone et al.Gut. 2011, Vol 60, Num 2, pp 156-165, issn 0017-5749, 10 p.Article

Synthesis of 3'-deoxy-3'-difluoromethyl azanucleosides from trans-4-hydroxy-L-prolineQIU, Xiao-Long; QING, Feng-Ling.Journal of organic chemistry. 2005, Vol 70, Num 10, pp 3826-3837, issn 0022-3263, 12 p.Article

Decitabine in chronic leukemiasISSA, Jean-Pierre J; BYRD, John C.Seminars in hematology. 2005, Vol 42, Num 3, pp S43-S49, issn 0037-1963, SUP2Article

Decitabine in myelodysplastic syndromesSABA, Hussain I; WIJERMANS, Pierre W.Seminars in hematology. 2005, Vol 42, Num 3, pp S23-S31, issn 0037-1963, SUP2Article

Clinical development of decitabine as a prototype for an epigenetic drug programROSENFELD, Craig S.Seminars in oncology. 2005, Vol 32, Num 5, pp 465-472, issn 0093-7754, 8 p.Article

5 -Azacytidine -induced methyltransferase-DNA adducts block DNA replication in vivoKENNY KUO, H; GRIFFITH, Jack D; KREUZER, Kenneth N et al.Cancer research (Baltimore). 2007, Vol 67, Num 17, pp 8248-8254, issn 0008-5472, 7 p.Article

Immunomodulatory effect of 5-azacytidine (5-azaC): potential role in the transplantation settingSANCHEZ-ABARCA, Luis I; GUTIERREZ-COSIO, Silvia; FLORES, Teresa et al.Blood. 2010, Vol 115, Num 1, pp 107-121, issn 0006-4971, 15 p.Article

8-Aza derivatives of 3-deazapurine nucleosides. Synthesis and in vitro evaluation of antiviral and antitumor activityFRANCHETTI, P; MESSINI, L; CAPPELLACCI, L et al.Antiviral chemistry & chemotherapy. 1993, Vol 4, Num 6, pp 341-352, issn 0956-3202Article

Approval summary : Azacitidine for treatment of myelodysplastic syndrome subtypesKAMINSKAS, Edvardas; FARRELL, Ann; WANG, Yong-Cheng et al.Clinical cancer research. 2005, Vol 11, Num 10, pp 3604-3608, issn 1078-0432, 5 p.Article

Characterization of dna demethylation effects induced by 5-Aza-2'-deoxycytidine in patients with myelodysplastic syndromeMUND, Cora; HACKANSON, Björn; STRESEMANN, Carlo et al.Cancer research (Baltimore). 2005, Vol 65, Num 16, pp 7086-7090, issn 0008-5472, 5 p.Article

Evaluation of a 7-day continuous intravenous infusion of decitabine: Inhibition of promoter-specific and global genomic DNA methylationSAMLOWSKI, Wolfram E; LEACHMAN, Sancy A; KARPF, Adam R et al.Journal of clinical oncology. 2005, Vol 23, Num 17, pp 3897-3905, issn 0732-183X, 9 p.Article

Decitabine in acute myeloid leukemiaLÜBBERT, Michael; MINDEN, Mark.Seminars in hematology. 2005, Vol 42, Num 3, pp S38-S42, issn 0037-1963, SUP2Article

Effects of tetrahydrouridine on pharmacokinetics and pharmacodynamics of oral decitabineLAVELLE, Donald; VAITKUS, Kestis; COVEY, Joseph et al.Blood. 2012, Vol 119, Num 5, pp 1240-1247, issn 0006-4971, 8 p.Article

DNA methylation changes after 5-Aza-2'-deoxycytidine therapy in patients with leukemiaYANG, Allen S; DOSHI, Ketan D; KANTARJIAN, Hagop M et al.Cancer research (Baltimore). 2006, Vol 66, Num 10, pp 5495-5503, issn 0008-5472, 9 p.Article

Complete remission of Sweet's syndrome after azacytidine treatment for concomitant myelodysplastic syndromeMARTINELLI, Sara; RIGOLIN, Gian Matteo; LEO, Genesio et al.International journal of hematology. 2014, Vol 99, Num 5, pp 663-667, issn 0925-5710, 5 p.Article

Prolonged Administration of Azacitidine With or Without Entinostat for Myelodysplastic Syndrome and Acute Myeloid Leukemia With Myelodysplasia-Related Changes: Results of the US Leukemia Intergroup Trial E1905PREBET, Thomas; ZHUOXIN SUN; PAIETTA, Elisabeth et al.Journal of clinical oncology. 2014, Vol 32, Num 12, pp 1242-1248, issn 0732-183X, 7 p.Article

5-Aza-2'-Deoxycytidine Enhances Maspin Expression and Inhibits Proliferation, Migration, and Invasion of the Bladder Cancer T24 Cell LineHUIHUI ZHANG; FAN QI; YOUHAN CAO et al.Cancer biotherapy & radiopharmaceuticals. 2013, Vol 28, Num 4, pp 343-350, issn 1084-9785, 8 p.Article

5-Azacytidine for the treatment of myelodysplastic syndromesKRAWCZYK, Janusz; KEANE, Niamh; FREEMAN, Ciara Louise et al.Expert opinion on pharmacotherapy. 2013, Vol 14, Num 9, pp 1255-1268, issn 1465-6566, 14 p.Article

5-aza-2'-Deoxycytidine Enhances the Radiosensitivity of Breast Cancer CellsLI WANG; YONG ZHANG; RONGQING LI et al.Cancer biotherapy & radiopharmaceuticals. 2013, Vol 28, Num 1, pp 34-44, issn 1084-9785, 11 p.Article

Anticancer efficacy of cisplatin and trichostatin A or 5-aza-2'-deoxycytidine on ovarian cancerMENG, F; SUN, G; ZHONG, M et al.British journal of cancer. 2013, Vol 108, Num 3, pp 579-586, issn 0007-0920, 8 p.Article

Decitabine: A Review of its Use in Older Patients with Acute Myeloid LeukaemiaCURRAN, Monique P.Drugs & aging. 2013, Vol 30, Num 6, pp 447-458, issn 1170-229X, 12 p.Article